Tarextumab
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Human |
| Target | Notch 2, Notch 3 |
| Clinical data | |
| Other names | OMP-59R5 |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6338H9804N1700O1990S48 |
| Molar mass | 143196.94 g·mol−1 |
Tarextumab (formerly OMP-59R5) is a fully human monoclonal antibody targeting the Notch 2/3 receptors. It is being tested as a possible treatment for cancer. In January 2015, the US FDA granted orphan drug designation to tarextumab for the treatment of pancreatic cancer and lung cancer.[1] Two early stage clinical trials have reported encouraging results.[1]
See also
[edit]- Notch signaling pathway, e.g. in embryo tissue development
References
[edit]
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |